GENERAL VASCULAR I
Total Payments
$1.5M
Transactions
20
Doctors
4
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $1.5M | 15 | 0 |
| 2020 | $52.63 | 5 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.5M | 15 | 100.0% |
| Food and Beverage | $52.63 | 5 | 0.0% |
Payments by Type
Research
$1.5M
15 transactions
General
$52.63
5 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Ablation with Confirmation of Colorectal Liver Metastases ACCLAIM Phase II Prospective Trial for Microwave Ablation as a Local Cure | Boston Scientific Corporation | $1.0M | 0 |
| Best Endovascular vs Best Surgical Therapy in Patients With Critical Limb Ischemia BEST CLI | Boston Scientific Corporation | $100,000 | 0 |
| Expert Consensus Statement: State of the Art and Current Use of IVUS in Non Coronary Vascular Disease Venous and Arterial | Boston Scientific Corporation | $88,078 | 0 |
| Thrombolysis versus re stenting in patients with age indeterminate in stent stenosis: Evaluating patient risk factors and histopathologic markers of acute and chronic venous stent thrombosis and optimal treatment strategies Khaja | Boston Scientific Corporation | $71,002 | 0 |
| Single session AngioJet ZelanteDVT assisted iliofemoral deep venous thrombectomy: A retrospective study of efficacy and durability | Boston Scientific Corporation | $59,120 | 0 |
| Heart Failure with Preserved Ejection FRaction and Symptomatic ObstrUctive IliofemorAl Venous DiseasE: A Pilot Cohort Study The PERSUADE Study | Boston Scientific Corporation | $50,850 | 0 |
| CREST 2 REGISTRY | Boston Scientific Corporation | $50,000 | 0 |
| RAPID | Boston Scientific Corporation | $50,000 | 0 |
| Does Junctional Reflux Impact Symptoms and Patient Reported Outcomes of Isolated Greater Saphenous Vein GSV Treatments in patients with isolated Venous | Boston Scientific Corporation | $46,250 | 0 |
| Comparison of early venous stenting versus physical therapy in the management of lower extremity lymphedema secondary to non thrombotic malignant venous stenosis | Boston Scientific Corporation | $5,000 | 0 |
Top Doctors Receiving Payments for GENERAL VASCULAR I
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Durham, NC | $1.5M | 15 |
| , M.D | Diagnostic Radiology | Pensacola, FL | $20.57 | 1 |
| , DPM | Foot & Ankle Surgery | Kirkland, WA | $15.61 | 1 |
| , M.D | Diagnostic Radiology | La Jolla, CA | $10.24 | 1 |
| , M.D., J.D | Diagnostic Radiology | La Jolla, CA | $6.21 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Device
- Total Payments $1.5M
- Total Doctors 4
- Transactions 20
About GENERAL VASCULAR I
GENERAL VASCULAR I is a device associated with $1.5M in payments to 4 healthcare providers, recorded across 20 transactions in the CMS Open Payments database. The primary manufacturer is BOSTON SCIENTIFIC CORPORATION.
Payment data is available from 2020 to 2021. In 2021, $1.5M was paid across 15 transactions to 0 doctors.
The most common payment nature for GENERAL VASCULAR I is "Unspecified" ($1.5M, 100.0% of total).
GENERAL VASCULAR I is associated with 10 research studies, including "Ablation with Confirmation of Colorectal Liver Metastases ACCLAIM Phase II Prospective Trial for Microwave Ablation as a Local Cure" ($1.0M).